Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
13 Febbraio 2025 - 8:11PM
Edgar (US Regulatory)
|
|
|
|
|
U.S. Securities and Exchange Commission
100 F Street, N.E. |
|
|
Washington, DC 20549 |
February 13, 2025
Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and
Section 13(r) of the Exchange Act
Dear Sirs:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of
1934, as amended, notice is hereby provided that Sanofi has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with
the Securities and Exchange Commission on February 13, 2025.
Sincerely,
|
| /s/ Alexandra Roger |
| Alexandra Roger |
| Head of Legal Corporate and Finance |
Siège social : 46, avenue de la Grande Armée, 75017 Paris - France - Tél.: +33
(0)1.53.77.40.00 - Fax : +33 (0)1.53.77.41.33 - www.sanofi.com
S.A. au capital de 2 526 245 442 € - 395 030 844 R.C.S.
Paris - Code APE 7010 Z - N° intracommunautaire : FR 88395030844
Grafico Azioni Sanofi (NASDAQ:SNY)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Sanofi (NASDAQ:SNY)
Storico
Da Feb 2024 a Feb 2025
